NALIRIFOX (liposomal irinotecan-based chemotherapy).
Phase 2Small molecule
NALIRIFOX (liposomal irinotecan-based chemotherapy). is one of 34 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Gemzar
GGynecologic Oncology Group
Preclinical
Byetta
AstraZenecaPreclinical
ABI-007
Bristol-Myers SquibbPreclinical
Alpha-Glucosidase Inhibitors
SanofiPreclinical
Active Comparator
ModernaPreclinical
Chemotherapy Agents
TakedaPreclinical
Meglitinides
SanofiPreclinical
NALIRIFOX (liposomal irinotecan-based chemotherapy).
SShandong Cancer Hospital and Institute
Phase 2
Secretin-Ferring
FerringPreclinical
Concurrent Lenvatinib
TTrans Tasman Radiation Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details